ANO1 and cancer: Notably, ANO1-mediated resistance to immunotherapy involves the induction of TGF-β production, recruitment of cancer-associated fibroblasts (CAFs), and the subsequent formation of an immunosuppressive milieu (Jiang F. et al., 2023; Mao et al., 2023).